208 related articles for article (PubMed ID: 34614409)
1. DRAK2 aggravates nonalcoholic fatty liver disease progression through SRSF6-associated RNA alternative splicing.
Li Y; Xu J; Lu Y; Bian H; Yang L; Wu H; Zhang X; Zhang B; Xiong M; Chang Y; Tang J; Yang F; Zhao L; Li J; Gao X; Xia M; Tan M; Li J
Cell Metab; 2021 Oct; 33(10):2004-2020.e9. PubMed ID: 34614409
[TBL] [Abstract][Full Text] [Related]
2. DRAK2-SRSF6-regulated RNA alternative splicing is a promising therapeutic target in NAFLD/NASH.
Dalamaga M; Liu J
Metabol Open; 2022 Mar; 13():100157. PubMed ID: 34917919
[No Abstract] [Full Text] [Related]
3. The RNA-binding profile of the splicing factor SRSF6 in immortalized human pancreatic β-cells.
Alvelos MI; Brüggemann M; Sutandy FR; Juan-Mateu J; Colli ML; Busch A; Lopes M; Castela Â; Aartsma-Rus A; König J; Zarnack K; Eizirik DL
Life Sci Alliance; 2021 Mar; 4(3):. PubMed ID: 33376132
[TBL] [Abstract][Full Text] [Related]
4. The American lifestyle-induced obesity syndrome diet in male and female rodents recapitulates the clinical and transcriptomic features of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
Harris SE; Poolman TM; Arvaniti A; Cox RD; Gathercole LL; Tomlinson JW
Am J Physiol Gastrointest Liver Physiol; 2020 Sep; 319(3):G345-G360. PubMed ID: 32755310
[TBL] [Abstract][Full Text] [Related]
5. Protein kinase STK25 regulates hepatic lipid partitioning and progression of liver steatosis and NASH.
Amrutkar M; Cansby E; Nuñez-Durán E; Pirazzi C; Ståhlman M; Stenfeldt E; Smith U; Borén J; Mahlapuu M
FASEB J; 2015 Apr; 29(4):1564-76. PubMed ID: 25609431
[TBL] [Abstract][Full Text] [Related]
6. Bax inhibitor-1 protects from nonalcoholic steatohepatitis by limiting inositol-requiring enzyme 1 alpha signaling in mice.
Lebeaupin C; Vallée D; Rousseau D; Patouraux S; Bonnafous S; Adam G; Luciano F; Luci C; Anty R; Iannelli A; Marchetti S; Kroemer G; Lacas-Gervais S; Tran A; Gual P; Bailly-Maitre B
Hepatology; 2018 Aug; 68(2):515-532. PubMed ID: 29457838
[TBL] [Abstract][Full Text] [Related]
7. Hepatic transcriptome signatures in patients with varying degrees of nonalcoholic fatty liver disease compared with healthy normal-weight individuals.
Suppli MP; Rigbolt KTG; Veidal SS; Heebøll S; Eriksen PL; Demant M; Bagger JI; Nielsen JC; Oró D; Thrane SW; Lund A; Strandberg C; Kønig MJ; Vilsbøll T; Vrang N; Thomsen KL; Grønbæk H; Jelsing J; Hansen HH; Knop FK
Am J Physiol Gastrointest Liver Physiol; 2019 Apr; 316(4):G462-G472. PubMed ID: 30653341
[TBL] [Abstract][Full Text] [Related]
8. Targeted Delivery of Stk25 Antisense Oligonucleotides to Hepatocytes Protects Mice Against Nonalcoholic Fatty Liver Disease.
Cansby E; Nuñez-Durán E; Magnusson E; Amrutkar M; Booten SL; Kulkarni NM; Svensson LT; Borén J; Marschall HU; Aghajan M; Mahlapuu M
Cell Mol Gastroenterol Hepatol; 2019; 7(3):597-618. PubMed ID: 30576769
[TBL] [Abstract][Full Text] [Related]
9. New insights into the characteristics of DRAK2 and its role in apoptosis: From molecular mechanisms to clinically applied potential.
Zheng Y; Li X; Kuang L; Wang Y
Front Pharmacol; 2022; 13():1014508. PubMed ID: 36386181
[TBL] [Abstract][Full Text] [Related]
10. SRSF6 regulates alternative splicing of genes involved in DNA damage response and DNA repair in HeLa cells.
Yang X; Zhan P; Feng S; Ji H; Tian W; Wang M; Cheng C; Song B
Oncol Rep; 2020 Nov; 44(5):1851-1862. PubMed ID: 32901876
[TBL] [Abstract][Full Text] [Related]
11. Zinc-induced modulation of SRSF6 activity alters Bim splicing to promote generation of the most potent apoptotic isoform BimS.
Hara H; Takeda T; Yamamoto N; Furuya K; Hirose K; Kamiya T; Adachi T
FEBS J; 2013 Jul; 280(14):3313-27. PubMed ID: 23648111
[TBL] [Abstract][Full Text] [Related]
12. SRSF6-regulated alternative splicing that promotes tumour progression offers a therapy target for colorectal cancer.
Wan L; Yu W; Shen E; Sun W; Liu Y; Kong J; Wu Y; Han F; Zhang L; Yu T; Zhou Y; Xie S; Xu E; Zhang H; Lai M
Gut; 2019 Jan; 68(1):118-129. PubMed ID: 29114070
[TBL] [Abstract][Full Text] [Related]
13. Degradation of splicing factor SRSF3 contributes to progressive liver disease.
Kumar D; Das M; Sauceda C; Ellies LG; Kuo K; Parwal P; Kaur M; Jih L; Bandyopadhyay GK; Burton D; Loomba R; Osborn O; Webster NJ
J Clin Invest; 2019 Aug; 129(10):4477-4491. PubMed ID: 31393851
[TBL] [Abstract][Full Text] [Related]
14. Comparison of Gene Expression Patterns Between Mouse Models of Nonalcoholic Fatty Liver Disease and Liver Tissues From Patients.
Teufel A; Itzel T; Erhart W; Brosch M; Wang XY; Kim YO; von Schönfels W; Herrmann A; Brückner S; Stickel F; Dufour JF; Chavakis T; Hellerbrand C; Spang R; Maass T; Becker T; Schreiber S; Schafmayer C; Schuppan D; Hampe J
Gastroenterology; 2016 Sep; 151(3):513-525.e0. PubMed ID: 27318147
[TBL] [Abstract][Full Text] [Related]
15. Disruption of hepatic small heterodimer partner induces dissociation of steatosis and inflammation in experimental nonalcoholic steatohepatitis.
Magee N; Zou A; Ghosh P; Ahamed F; Delker D; Zhang Y
J Biol Chem; 2020 Jan; 295(4):994-1008. PubMed ID: 31831621
[TBL] [Abstract][Full Text] [Related]
16. Current pharmacological therapies for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
Takahashi Y; Sugimoto K; Inui H; Fukusato T
World J Gastroenterol; 2015 Apr; 21(13):3777-85. PubMed ID: 25852263
[TBL] [Abstract][Full Text] [Related]
17. Alternative RNA Splicing in Fatty Liver Disease.
Wu P; Zhang M; Webster NJG
Front Endocrinol (Lausanne); 2021; 12():613213. PubMed ID: 33716968
[TBL] [Abstract][Full Text] [Related]
18. Pyruvate dehydrogenase kinase 4 mediates lipogenesis and contributes to the pathogenesis of nonalcoholic steatohepatitis.
Zhang M; Zhao Y; Li Z; Wang C
Biochem Biophys Res Commun; 2018 Jan; 495(1):582-586. PubMed ID: 29128353
[TBL] [Abstract][Full Text] [Related]
19. Relative strength of 5' splice-site strength defines functions of SRSF2 and SRSF6 in alternative splicing of Bcl-x pre-mRNA.
Choi N; Liu Y; Oh J; Ha J; Ghigna C; Zheng X; Shen H
BMB Rep; 2021 Mar; 54(3):176-181. PubMed ID: 33050987
[TBL] [Abstract][Full Text] [Related]
20. STK25 is a critical determinant in nonalcoholic steatohepatitis.
Amrutkar M; Chursa U; Kern M; Nuñez-Durán E; Ståhlman M; Sütt S; Borén J; Johansson BR; Marschall HU; Blüher M; Mahlapuu M
FASEB J; 2016 Oct; 30(10):3628-3643. PubMed ID: 27421788
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
